There is a new Alzheimer’s drug called Leqembi that has been FDA-approved in the U.S. It slows down the progression of Alzheimer’s and trials have shown a 27% reduction in the illness. But the drug has to be administered early on in the progression of Alzheimer’s. Joanne Bracken is the CEO of the Alzheimer Society of Saskatchewan and joins Gormley to discuss the promising results and what needs to happen next before it comes to Canada.